TC Biopharm (Holdings) Plc (TCBP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Maxim 1
Motherwell, ML1 4WR
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 14 1433 7557
Website
Sector
Healthcare
Industry
Biotechnology
Employees
41
First IPO Date
February 11, 2022
| Name | Title | Pay | Year Born |
| Bryan L. Kobel | Chief Executive Officer & Director | 544,560 | 1979 |
| Martin E. Thorp | Chief Financial Officer & Director | 410,521 | 1952 |
| Lauren Bor | Head of Commercial Development Division | 0 | N/A |
| Christopher Camarra | Executive Vice President of Communications | 0 | N/A |
Operating as a clinical-stage biopharmaceutical entity, TC Biopharm (Holdings) Plc is dedicated to pioneering immunotherapy solutions, leveraging its proprietary allogeneic gamma delta T cell platform. Its developmental portfolio includes OmnImmune, an unmodified cellular therapy aimed at acute myeloid leukemia, and ImmuniStim, another unmodified cellular therapy designed to combat COVID-19. The company was established in 2013 and is headquartered in Motherwell, United Kingdom.